UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

Novo’s Wegovy and Eli Lilly’s Zepbound are listed at $1,086 and $1,059 ... PBMs such as CVS Caremark, Cigna’s Express Scripts ...

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...